FINWIRES · TerminalLIVE
FINWIRES

HKG:3696

9 stories mentioning HKG:3696Updated 1d ago

Every FINWIRES story that references HKG:3696, newest first.

Asia

InSilico Medicine Completes First Human Dosing of Parkinson's Disease Drug in Phase 1 Trial

InSilico Medicine Cayman (HKG:3696) completed first-in-human dosing in a phase 1 clinical trial of ISM8969, according to a Wednesday Hong Kong bourse filing.The oral NLRP3 inhibitor is being developed to treat chronic neuroinflammation and central nervous system disorders, including Parkinson's disease.The milestone marks the first clinical achievement under the company's co-development collaboration with Hygtia Therapeutics.

HKG:3696
Asia

Insilico Medicine to Join FTSE Global Equity Index Series

Insilico Medicine (HKG:3696) will be added to the FTSE Global Equity Index Series following FTSE Russell's quarterly review, according to a Monday Hong Kong bourse filing.The artificial intelligence drug discovery company will join the FTSE Global Small Cap Index, FTSE Global All Cap Index, and FTSE Global Total Cap Index, with the changes taking effect on June 22.

HKG:3696
Asia

InSilico Medicine Says No Decision Made on Abu Dhabi Secondary Listing

InSilico Medicine (HKG:3696) said it has not made any concrete decision on a secondary listing at this stage and will make further announcements if there are any material developments, according to a Wednesday Hong Kong bourse filing.Bloomberg reported earlier, citing people familiar with the matter, that the AI-driven drug discovery company was considering a secondary listing in Abu Dhabi, potentially becoming the first company from outside the Gulf to list shares on a regional exchange.The report said InSilico Medicine had held preliminary discussions about a listing on the Abu Dhabi Securities Exchange as early as this year.

HKG:3696
Asia

Market Chatter: InSilico Medicine Considering Secondary Listing in Abu Dhabi

InSilico Medicine (HKG:3696) is considering listing in Abu Dhabi less than a year after going public in Hong Kong, Bloomberg News reported Tuesday.The Boston-based biotechnology firm has held preliminary discussions to list shares on the Abu Dhabi Securities Exchange as early as this year, the report said, citing people familiar with the matter.InSilico Medicine was listed in Hong Kong in December 2025, raising HK$2.28 billion from its IPO. The Tencent Holdings-backed (HKG:0700) drug discovery company had a stellar trading debut with shares closing 25% higher than their IPO price of HK$24.05 in their first day of trading.Insilico has yet to respond to' request for comment at press time.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

HKG:0700HKG:3696
Asia

InSilico Medicine to Join Hang Seng Biotech Index as Constituent Stock

InSilico Medicine (HKG:3696) will be included as a constituent stock of the Hang Seng Biotech Index effective the close of market on June 5, according to a Tuesday Hong Kong bourse filing.The AI-driven drug discovery firm believes the inclusion reflects the capital market's recognition of its long-term growth potential.

HKG:3696
Asia

InSilico Medicine Invests $105 Million in Wealth Management Products

InSilico Medicine (HKG:3696) invested $105 million in wealth management products offered by CMB International and JPMorgan, according to a Hong Kong bourse filing Thursday.The AI-driven drug discovery firm invested $50 million in a money market fund managed by CMB International Asset Management with an expected 3.99% annualized rate of return; $50 million in a variable net asset value money market fund by JPMorgan Asset Management with an expected 3.85% annualized rate of return; and a further $5 million in a dual-currency deposit issued by JPMorgan Chase Bank with an expected 4.68% rate of return.The subscriptions were made with the view of "enhancing returns on surplus cash," the firm said.

HKG:3696
Asia

Insilico Medicine Wins China IND Nod for IPF Inhalation Therapy

InSilico Medicine (HKG:3696) said its investigational new drug application for an inhaled formulation of Rentosertib has been approved by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The company said the drug is intended for the treatment of idiopathic pulmonary fibrosis.The approval supports a Phase 1 clinical study to evaluate safety, tolerability, and pharmacokinetics, the filing said.

HKG:3696
Asia

Insilico Medicine Nominates AI-Developed Brain Cancer Drug Candidate

Insilico Medicine (HKG:3696) has nominated a new preclinical drug candidate for glioblastoma using its artificial intelligence platform, according to a Friday Hong Kong bourse filing.The candidate, ISM0387, was developed by the company's United Arab Emirates team using its Pharma.AI system and progressed from design to optimization in under 12 months.Insilico said the drug showed improved activity, selectivity, and brain penetration in early studies, with potential as a treatment for brain cancer.

HKG:3696
Asia

InSilico Medicine Grants 3.7 Million RSUs Under Incentive Scheme

InSilico Medicine (HKG:3696) granted a little over 3.7 million restricted share units (RSUs) to certain participants under a post-IPO RSU scheme, according to a Tuesday Hong Kong bourse filing.The granting of the RSUs is subject to the fulfillment of the relevant performance targets, the AI-driven drug discovery and development company said.The firm now has around 24.2 million shares available for future grants under its RSU and share option incentive plans, of which 2.8 million shares will be available for future grant to service providers within the scheme mandate limit.

HKG:3696

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:3696 in your portfolio
WheelAI
WheelAI
Analyze HKG:3696 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:3696